MARKET

IMUX

IMUX

Immunic Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.11
+0.03
+0.49%
After Hours: 6.11 0 0.00% 16:01 05/27 EDT
OPEN
6.17
PREV CLOSE
6.08
HIGH
6.35
LOW
5.97
VOLUME
156.03K
TURNOVER
0
52 WEEK HIGH
15.12
52 WEEK LOW
4.960
MARKET CAP
186.60M
P/E (TTM)
-2.0138
1D
5D
1M
3M
1Y
5Y
Piper Sandler Adjusts Immunic's Price Target to $39 From $71, Reiterates Overweight Rating
MT Newswires · 05/18 07:03
Duane Nash Is The Executive Chairman of Immunic, Inc. (NASDAQ:IMUX) And They Just Picked Up 166% More Shares
Whilst it may not be a huge deal, we thought it was good to see that the Immunic, Inc. ( NASDAQ:IMUX ) Executive...
Simply Wall St. · 05/15 12:38
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 05/10 13:23
Immunic: Q1 Earnings Insights
  Immunic (NASDAQ:IMUX) reported its Q1 earnings results on Tuesday, May 10, 2022 at 06:30 AM. Here's what investors need to know about the announcement.
Benzinga · 05/10 12:46
Immunic Q1 EPS $(0.74) Beats $(0.80) Estimate
Immunic (NASDAQ:IMUX) reported quarterly losses of $(0.74) per share which beat the analyst consensus estimate of $(0.80) by 7.5 percent. This is a 54.6 percent increase over losses of $(1.63) per share from the same
Benzinga · 05/10 10:55
Immunic GAAP EPS of -$0.74 beats by $0.05
Immunic press release (NASDAQ:IMUX): Q1 GAAP EPS of -$0.74 beats by $0.05. Cash and Cash Equivalents as of March 31, 2022 were $95.7 million, which does not include the additional
Seekingalpha · 05/10 10:33
Earnings Scheduled For May 10, 2022
  Companies Reporting Before The Bell • The Middleby (NASDAQ:MIDD) is expected to report quarterly earnings at $2.10 per share on revenue of $935.99 million.
Benzinga · 05/10 09:18
-- Earnings Flash (IMUX) IMMUNIC Reports Q1 Loss $-0.74, vs. Street Est of $-0.76
MT Newswires · 05/10 06:43
More
No Data
Learn about the latest financial forecast of IMUX. Analyze the recent business situations of Immunic Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

37.50%Strong Buy
62.50%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average IMUX stock price target is 50.50 with a high estimate of 64.00 and a low estimate of 25.00.
High64.00
Average50.50
Low25.00
Current 6.11
EPS
Actual
Estimate
-0.66-0.49-0.33-0.16
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 100
Institutional Holdings: 17.79M
% Owned: 58.27%
Shares Outstanding: 30.54M
TypeInstitutionsShares
Increased
20
2.45M
New
16
2.35M
Decreased
29
696.83K
Sold Out
3
179.06K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.72%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
Chairman/Executive Director
Duane Nash
President/Chief Executive Officer/Director
Daniel Vitt
Chief Financial Officer
Glenn Whaley
Chief Scientific Officer
Hella Kohlhof
General Counsel
Inderpal Singh
Other
Andreas Muehler
Other
Patrick Walsh
Independent Director
Tamar Howson
Independent Director
Jorg Neermann
Independent Director
Vincent Ossipow
Independent Director
Barclay Phillips
Independent Director
Jan Van den Bossche
No Data
No Data
About IMUX
Immunic, Inc., formerly Vital Therapies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing oral therapies for the treatment of chronic inflammatory and autoimmune diseases. The Company is developing three small molecule products: IMU-838 is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. The Company’s lead development program, IMU-838, is in Phase II clinical development for ulcerative colitis and relapsing-remitting multiple sclerosis, with an additional Phase II trial in Crohn’s disease.

Webull offers kinds of Immunic Inc stock information, including NASDAQ:IMUX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMUX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IMUX stock methods without spending real money on the virtual paper trading platform.